loading
Travere Therapeutics Inc stock is traded at $17.30, with a volume of 728.24K. It is down -2.50% in the last 24 hours and down -3.32% over the past month. Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
See More
Previous Close:
$17.72
Open:
$17.69
24h Volume:
728.24K
Relative Volume:
0.40
Market Cap:
$1.52B
Revenue:
$203.45M
Net Income/Loss:
$-351.45M
P/E Ratio:
-3.8267
EPS:
-4.52
Net Cash Flow:
$-369.41M
1W Performance:
-9.21%
1M Performance:
-3.32%
6M Performance:
+185.10%
1Y Performance:
+195.34%
1-Day Range:
Value
$16.86
$17.86
1-Week Range:
Value
$16.86
$19.51
52-Week Range:
Value
$5.12
$20.33

Travere Therapeutics Inc Stock (TVTX) Company Profile

Name
Name
Travere Therapeutics Inc
Name
Phone
888-969-7879
Name
Address
3611 VALLEY CENTRE DR, SAN DIEGO
Name
Employee
380
Name
Twitter
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
TVTX's Discussions on Twitter

Compare TVTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
TVTX 17.30 1.52B 203.45M -351.45M -369.41M -4.52
VRTX 467.14 119.83B 10.63B -479.80M -1.35B 13.33
REGN 760.26 83.28B 13.85B 4.65B 3.32B 35.06
ARGX 565.93 33.74B 1.86B -40.29M -1.28B -4.16
ALNY 230.62 30.38B 2.09B -332.26M 16.06M -4.14
BNTX 101.14 24.08B 3.30B -501.07M 1.03B 11.54

Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-27-24 Downgrade Guggenheim Buy → Neutral
Dec-05-23 Upgrade Citigroup Neutral → Buy
Nov-20-23 Initiated Citigroup Neutral
Sep-22-23 Downgrade Wells Fargo Overweight → Equal Weight
Sep-21-23 Downgrade William Blair Outperform → Mkt Perform
Sep-06-23 Resumed Evercore ISI Outperform
Jul-21-23 Initiated JP Morgan Overweight
Jun-07-23 Resumed Piper Sandler Neutral
May-22-23 Initiated TD Cowen Outperform
May-05-23 Upgrade Bryan Garnier Sell → Neutral
Mar-01-23 Initiated Guggenheim Buy
Feb-21-23 Upgrade Wedbush Neutral → Outperform
Dec-14-22 Initiated Stifel Hold
Dec-05-22 Initiated Wells Fargo Overweight
Sep-21-22 Initiated Bryan Garnier Sell
Jul-14-22 Resumed Canaccord Genuity Buy
Mar-31-22 Initiated Piper Sandler Overweight
Feb-28-22 Initiated H.C. Wainwright Buy
May-26-21 Downgrade Wedbush Outperform → Neutral
View All

Travere Therapeutics Inc Stock (TVTX) Latest News

pulisher
03:46 AM

Los Angeles Capital Management LLC Sells 56,866 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat

03:46 AM
pulisher
Nov 15, 2024

When (TVTX) Moves Investors should Listen - Stock Traders Daily

Nov 15, 2024
pulisher
Nov 15, 2024

Exploring Three High Growth Tech Stocks in the United States - Simply Wall St

Nov 15, 2024
pulisher
Nov 15, 2024

ARMISTICE CAPITAL, LLC Acquires Significant Stake in Travere The - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Woodline Partners LP Expands Stake in Travere Therapeutics Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Deep Track Capital, LP Reduces Stake in Travere Therapeutics Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $22.00 - MarketBeat

Nov 14, 2024
pulisher
Nov 13, 2024

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 13, 2024
pulisher
Nov 13, 2024

Travere Therapeutics Awards 24,400 RSUs to New Employees in Talent Acquisition Push | TVTX Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

Alport Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Eloxx Pharmac, Biogen, River 3 Renal Corp, Travere Therapeutics, Chinook Therapeutics - The Globe and Mail

Nov 13, 2024
pulisher
Nov 13, 2024

Travere Therapeutics Completes $143.8 Million Public Offering - Marketscreener.com

Nov 13, 2024
pulisher
Nov 12, 2024

Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares - The Manila Times

Nov 12, 2024
pulisher
Nov 11, 2024

3 Under-the-Radar Healthcare Companies - sharewise

Nov 11, 2024
pulisher
Nov 11, 2024

3 Under-the-Radar Healthcare Companies to Watch - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

Unitedhealth Group Inc (UNH-N) QuotePress Release - The Globe and Mail

Nov 11, 2024
pulisher
Nov 10, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Nov 10, 2024
pulisher
Nov 09, 2024

Travere Therapeutics (NASDAQ:TVTX) Reaches New 12-Month HighHere's What Happened - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

TVTX stock soars to 52-week high, hits $19.29 amid robust gains - Investing.com India

Nov 08, 2024
pulisher
Nov 08, 2024

Latham & Watkins Advises on Travere Therapeutics’ Public Offering of Common Stock - Latham & Watkins LLP

Nov 08, 2024
pulisher
Nov 08, 2024

Travere Therapeutics plans public stock offering By Investing.com - Investing.com Australia

Nov 08, 2024
pulisher
Nov 07, 2024

Travere Therapeutics Announces Pricing of Public Offering of Common Stock - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Travere Therapeutics Announces Pricing of Public Offering of Common Stock - Benzinga

Nov 07, 2024
pulisher
Nov 07, 2024

Travere Therapeutics plans public stock offering - Investing.com India

Nov 07, 2024
pulisher
Nov 07, 2024

Travere Therapeutics Launches Public Stock Offering, Led by Jefferies & Leerink | TVTX Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 05, 2024

Travere Therapeutics' SWOT analysis: filspari approval boosts rare disease stock outlook - Investing.com UK

Nov 05, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in Travere Therapeuti - GuruFocus.com

Nov 05, 2024
pulisher
Nov 04, 2024

Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 04, 2024
pulisher
Nov 04, 2024

Travere Therapeutics to Present at Upcoming Investor Conferences - The Manila Times

Nov 04, 2024
pulisher
Nov 03, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Holdings Raised by Emerald Mutual Fund Advisers Trust - MarketBeat

Nov 03, 2024
pulisher
Nov 03, 2024

Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Scotiabank Analyst Says - Defense World

Nov 03, 2024
pulisher
Nov 01, 2024

TVTXTravere Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Nov 01, 2024
pulisher
Nov 01, 2024

Scotiabank Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Evercore ISI raises Travere Therapeutics target to $33 By Investing.com - Investing.com Australia

Nov 01, 2024
pulisher
Nov 01, 2024

Travere Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 01, 2024
pulisher
Nov 01, 2024

Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amid Operational Challenges - GuruFocus.com

Nov 01, 2024
pulisher
Nov 01, 2024

Travere Therapeutics Boosts Sales with FILSPARI Approval - TipRanks

Nov 01, 2024
pulisher
Oct 31, 2024

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry - Simply Wall St

Oct 31, 2024
pulisher
Oct 31, 2024

Travere: Q3 Earnings Snapshot - The Washington Post

Oct 31, 2024
pulisher
Oct 31, 2024

Travere Therapeutics earnings beat by $1.34, revenue topped estimates - Investing.com Australia

Oct 31, 2024
pulisher
Oct 31, 2024

Travere Therapeutics Inc Reports Q3 2024 Revenue of $62.9 Millio - GuruFocus.com

Oct 31, 2024
pulisher
Oct 31, 2024

Travere Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times

Oct 31, 2024
pulisher
Oct 30, 2024

Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Report Preview: What to Expect - GuruFocus.com

Oct 30, 2024
pulisher
Oct 29, 2024

TD Cowen reiterates Buy on Travere shares after PARASOL findings By Investing.com - Investing.com Canada

Oct 29, 2024
pulisher
Oct 29, 2024

Semanteon Capital Management LP Purchases Shares of 36,699 Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat

Oct 29, 2024

Travere Therapeutics Inc Stock (TVTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Travere Therapeutics Inc Stock (TVTX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
LYONS GARY A
Director
Oct 04 '24
Sale
14.73
40,000
589,101
51,000
$18.94
price up icon 3.39%
$75.94
price down icon 0.01%
$39.03
price up icon 6.21%
$360.04
price down icon 0.87%
$187.60
price down icon 1.35%
$99.70
price down icon 0.06%
Cap:     |  Volume (24h):